A new role for α-synuclein in Parkinson's disease: Alteration of ER–mitochondrial communication

Movement Disorders

Volumn 30, Issue 8, 2015, Pages 1026-1033

  Guardia Laguarta, Cristina ^a   Area Gomez, Estela ^a   Schon, Eric A ^a   Przedborski, Serge ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

MAM; Parkinson's Disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; CELL COMMUNICATION; CELLULAR DISTRIBUTION; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; HUMAN; MITOCHONDRION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; INTRACELLULAR MEMBRANE; METABOLISM;

ALPHA-SYNUCLEIN; ENDOPLASMIC RETICULUM; HUMANS; INTRACELLULAR MEMBRANES; MITOCHONDRIA; PARKINSON DISEASE;

EID: 84929783342     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26239     Document Type: Article

References (130)

1. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-1199.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
3. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding α-synuclein. Am J Hum Genet 1999;65:555-558.
4. Spira PJ, Sharpe DM, Halliday G, et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann Neurol 2001;49:313-319.
5. Ki C-S, Stavrou EF, Davanos N, et al. The Ala53Thr mutation in the α-synuclein gene in a Korean family with Parkinson disease. Clin Genet 2007;71:471-473.
6. Choi JM, Woo MS, Ma H-I, et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008;9:263-269.
7. Puschmann A, Ross OA, Vilariño-Güell C, et al. A Swedish family with de novo α-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009;15:627-632.
8. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
9. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-173.
10. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. α-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013;28:811-813.
11. Lesage S, Anheim M, Letournel F, et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013;73:459-471.
12. Proukakis C, Dudzik CG, Brier T, et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013;80:1062-1064.
13. Chartier-Harlin M-C, Kachergus J, Roumier C, et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
14. Ibáñez P, Lesage S, Janin S, et al. α-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 2009;66:102-108.
15. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
16. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol 2004;55:174-179.
17. Alonso-Canovas A, Katschnig P, Tucci A, et al. Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease: expanding the spectrum: case report and literature review. Mov Disord 2010;25:1506-1509.
18. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89:691-694.
19. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
20. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475.
21. Dauer W, Kholodilov N, Vila M, et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002;99:14524-14529.
22. Maroteaux L, Scheller RH. The rat brain synucleins: family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 1991;11:335-343.
23. Fortin DL, Troyer MD, Nakamura K, et al. Lipid rafts mediate the synaptic localization of α-synuclein. J Neurosci 2004;24:6715-6723.
24. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 2000;20:6365-6373.
25. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-2815.
26. Gonçalves S, Outeiro TF. Assessing the subcellular dynamics of α-synuclein using photoactivation microscopy. Mol Neurobiol 2013;47:1081-1092.
27. McLean PJ, Ribich S, Hyman BT. Subcellular localization of α-synuclein in primary neuronal cultures: effect of missense mutations. J Neural Transm Suppl 2000;58:53-63.
28. Mori F, Tanji K, Yoshimoto M, et al. Immunohistochemical comparison of aa- and beta-synuclein in adult rat central nervous system. Brain Res 2002;941:118-126.
29. Goers J, Manning-Bog AB, McCormack AL, et al. Nuclear localization of α-synuclein and its interaction with histones. Biochemistry 2003;42:8465-8471.
30. Kontopoulos E, Parvin JD, Feany MB. α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006;15:3012-3023.
31. Specht CG, Tigaret CM, Rast GF, et al. Subcellular localisation of recombinant aa- and gamma-synuclein. Mol Cell Neurosci 2005;28:326-334.
32. Cole NB, Dieuliis D, Leo P, et al. Mitochondrial translocation of α-synuclein is promoted by intracellular acidification. Exp Cell Res 2008;314:2076-2089.
33. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008;283:9089-9100.
34. Shavali S, Brown-Borg HM, Ebadi M, Porter J. Mitochondrial localization of α-synuclein protein in α-synuclein overexpressing cells. Neurosci Lett 2008;439:125-128.
35. Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 2010;26:211-233.
36. Jensen MB, Bhatia VK, Jao CC, et al. Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12. J Biol Chem 2011;286:42603-42614.
37. Middleton ER, Rhoades E. Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys J 2010;99:2279-2288.
38. Kubo S, Nemani VM, Chalkley RJ, et al. A combinatorial code for the interaction of α-synuclein with membranes. J Biol Chem 2005;280:31664-31672.
39. Loeb V, Yakunin E, Saada A, Sharon R. The transgenic overexpression of αα-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem 2010;285:7334-7343.
40. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010;486:235-239.
41. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability: a point of convergence in parkinsonian neurodegeneration? J Neurochem 2009;110:1514-1522.
42. Lee H-J, Khoshaghideh F, Lee S, Lee S-J. Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. Eur J Neurosci 2006;24:3153-3162.
43. Weihofen A, Thomas KJ, Ostaszewski BL, et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009;48:2045-2052.
44. Yang F, Jiang Q, Zhao J, et al. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 2005;280:17154-17162.
45. Chan CS, Guzman JN, Ilijic E, et al. “Rejuvenation” protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086.
46. Mosharov E V, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62:218-229.
47. Schapira AH V. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7:97-109.
48. Gasser T. Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog Brain Res 2010;183:3-20.
49. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010;468:696-700.
50. Martin I, Dawson VL, Dawson TM. The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res 2010;183:21-41.
51. Obeso JA. Modeling clinical features of neurodegeneration. Nat Med 2010;16:1372.
52. Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 2010;47:175-182.
53. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. What causes the death of dopaminergic neurons in Parkinson's disease? Prog Brain Res 2010;183:59-77.
54. Schon EA, Przedborski S. Mitochondria: the next (neurode)generation. Neuron 2011;70:1033-1053.
55. Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 2013;155:1351-1364.
56. Li W-W, Yang R, Guo J-C, et al. Localization of α-synuclein to mitochondria within midbrain of mice. Neuroreport 2007;18:1543-1546.
57. Parihar MS, Parihar A, Fujita M, et al. Mitochondrial association of α-synuclein causes oxidative stress. Cell Mol Life Sci 2008;65:1272-1284.
58. Perez RG, Waymire JC, Lin E, et al. A role for a-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002;22:3090-3099.
59. Zheng YZ, Berg KB, Foster LJ. Mitochondria do not contain lipid rafts, and lipid rafts do not contain mitochondrial proteins. J Lipid Res 2009;50:988-998.
60. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol 2009;19:81-88.
61. Hayashi T, Fujimoto M. Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol Pharmacol 2010;77:517-528.
62. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 2012;31:4106-4123.
63. Fujimoto M, Hayashi T, Su T-P. The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria. Biochem Biophys Res Commun 2012;417:635-639.
64. Williamson CD, Zhang A, Colberg-Poley AM. The human cytomegalovirus protein UL37 exon 1 associates with internal lipid rafts. J Virol 2011;85:2100-2111.
65. 2+: molecular determinants and functional consequences. Physiol Rev 2006;86:369-408.
66. Voelker DR. Genetic and biochemical analysis of non-vesicular lipid traffic. Annu Rev Biochem 2009;78:827-856.
67. Csordás G, Hajnóczky G. SR/ER-mitochondrial local communication: calcium and ROS. Biochim Biophys Acta 2009;1787:1352-1362.
68. Simmen T, Lynes EM, Gesson K, Thomas G. Oxidative protein folding in the endoplasmic reticulum: tight links to the mitochondria-associated membrane (MAM). Biochim Biophys Acta 2010;1798:1465-1473.
69. Pinton P, Giorgi C, Pandolfi PP. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ 2011;18:1450-1456.
70. Patergnani S, Suski JM, Agnoletto C, et al. Calcium signaling around mitochondria associated membranes (MAMs). Cell Commun Signal 2011;9:19.
71. Lee H-J, Khoshaghideh F, Lee S, Lee S-J. Impairment of microtubule-dependent trafficking by overexpression of a-synuclein. Eur J Neurosci 2006;24:3153-3162.
72. Weihofen A, Thomas KJ, Ostaszewski BL, et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009;48:2045-2052.
73. 2+ cross-talk. Proc Natl Acad Sci U S A 2011;108:2777-2782.
74. Hedskog L, Pinho CM, Filadi R, et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. Proc Natl Acad Sci U S A 2013;110:7916-7921.
75. Stoica R, De Vos KJ, Paillusson S, et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by amyotrophic lateral sclerosis/FTD-associated TDP-43. Nat Commun 2014;5:3996.
76. Calì T, Ottolini D, Negro A, Brini M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem 2012;287:17914-17929.
77. Area-Gomez E, de Groof AJC, Boldogh I, et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 2009;175:1810-1816.
78. De Franceschi G, Frare E, Pivato M, et al. Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J Biol Chem 2011;286:22262-22274.
79. Fantini J, Yahi N. Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: key role of tyrosine 39 in membrane insertion. J Mol Biol 2011;408:654-669.
80. Madeira A, Yang J, Zhang X, et al. Caveolin-1 interacts with a-synuclein and mediates toxic actions of cellular a-synuclein overexpression. Neurochem Int 2011;59:280-289.
81. Zabrocki P, Bastiaens I, Delay C, et al. Phosphorylation, lipid raft interaction and traffic of a-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 2008;1783:1767-1780.
82. Lv J-H, He L, Sui S-F. Lipid rafts association of synaptotagmin I on synaptic vesicles. Biochem Biokhimiia 2008;73:283-288.
83. Mavlyutov TA, Epstein ML, Liu P, et al. Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N'-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience 2012;206:60-68.
84. Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131:596-610.
85. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of a-synuclein secondary structure upon binding to synthetic membranes J Biol Chem 1998;273:9443-9449.
86. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson Disease-associated protein a-synuclein. J Biol Chem 2011;286:20710-20726.
87. Voelker DR. Bridging gaps in phospholipid transport. Trends Biochem Sci 2005;30:396-404.
88. Guardia-Laguarta C, Area-Gomez E, Rüb C, et al. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 2014;34:249-259.
89. Guardia-Laguarta C, Area-Gomez E, Rüb C, et al. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 2014;34:249-259.
90. Fujisawa H, Okuno S. Regulatory mechanism of tyrosine hydroxylase activity. Biochem Biophys Res Commun 2005;338:271-276.
91. Dunkley PR, Bobrovskaya L, Graham ME, et al. Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 2004;91:1025-1043.
92. Campbell DG, Hardie DG, Vulliet PR. Identification of four phosphorylation sites in the N-terminal region of tyrosine hydroxylase. J Biol Chem 1986;261:10489-10492.
93. Pigeon D, Ferrara P, Gros F, Thibault J. Rat pheochromocytoma tyrosine hydroxylase is phosphorylated on serine 40 by an associated protein kinase. J Biol Chem 1987;262:6155-6158.
94. Bobrovskaya L, Dunkley PR, Dickson PW. Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells. J Neurochem 2004;90:857-864.
95. Berresheim U, Kuhn DM. Dephosphorylation of tyrosine hydroxylase by brain protein phosphatases: a predominant role for type 2A. Brain Res 1994;637:273-276.
96. Haavik J, Schelling DL, Campbell DG, et al. Identification of protein phosphatase 2A as the major tyrosine hydroxylase phosphatase in adrenal medulla and corpus striatum: evidence from the effects of okadaic acid. FEBS Lett 1989;251:36-42.
97. Leal RB, Sim ATR, Gonçalves CAS, Dunkley PR. Tyrosine hydroxylase dephosphorylation by protein phosphatase 2A in bovine adrenal chromaffin cells. Neurochem Res 2002;27:207-213.
98. Saraf A, Virshup DM, Strack S. Differential expression of the B'beta regulatory subunit of protein phosphatase 2A modulates tyrosine hydroxylase phosphorylation and catecholamine synthesis. J Biol Chem 2007;282:573-580.
99. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011;508:1-12.
100. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci 2004;117:1875-1884.
101. Berg D, Holzmann C, Riess O. 14-3-3 Proteins in the nervous system. Nat Rev Neurosci 2003;4:752-762.
102. Bustad HJ, Skjaerven L, Ying M, et al. The peripheral binding of 14-3-3γ to membranes involves isoform-specific histidine residues. PLoS One 2012;7:e49671.
103. Kleppe R, Rosati S, Jorge-Finnigan A, et al. Phosphorylation dependence and stoichiometry of the complex formed by tyrosine hydroxylase and 14-3-3γ. Mol Cell Proteomics 2014;13:2017-2030.
104. Hritz J, Byeon I-JL, Krzysiak T, et al. Dissection of binding between a phosphorylated tyrosine hydroxylase peptide and 14-3-3?: A complex story elucidated by NMR. Biophys J 2014;107:2185-2194.
105. Kleppe R, Toska K, Haavik J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J Neurochem 2001;77:1097-1107.
106. Obsilova V, Nedbalkova E, Silhan J, et al. The 14-3-3 protein affects the conformation of the regulatory domain of human tyrosine hydroxylase. Biochemistry 2008;47:1768-1777.
107. Wang J, Lou H, Pedersen CJ, et al. 14-3-3Zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 2009;284:14011-14019.
108. Baxter HC, Liu W-G, Forster JL, et al. Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain. Neuroscience 2002;109:5-14.
109. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739-29752.
110. Fujiwara H, Hasegawa M, Dohmae N, et al. a-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
111. Bergeron M, Motter R, Tanaka P, et al. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Neuroscience 2014;256:72-82.
112. Hara S, Arawaka S, Sato H, et al. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. Mol Biol Cell 2013;24:1649-1660, S1-S3.
113. Sato H, Arawaka S, Hara S, et al. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 2011;31:16884-16894.
114. Lee K-W, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci 2011;31:6963-6971.
115. Peng X, Peng XM, Tehranian R, et al. A-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005;118:3523-3530.
116. Ostrerova N, Petrucelli L, Farrer M, et al. a-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999;19:5782-5791.
117. Lou H, Montoya SE, Alerte TNM, et al. Serine 129 phosphorylation reduces the ability of a-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 2010;285:17648-17661.
118. Wu B, Liu Q, Duan C, et al. Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells. Acta Histochem 2011;113:32-35.
119. Xu J, Kao S-Y, Lee FJS, et al. Dopamine-dependent neurotoxicity of a-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-606.
120. Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 2000;275:26515-26522.
121. Kuwahara T, Tonegawa R, Ito G, et al. Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem 2012;287:7098-7109.
122. Giorgi C, Ito K, Lin H-K, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010;330:1247-1251.
123. Schindler CK, Heverin M, Henshall DC. Isoform- and subcellular fraction-specific differences in hippocampal 14-3-3 levels following experimentally evoked seizures and in human temporal lobe epilepsy. J Neurochem 2006;99:561-569.
124. Milner TA. Ultrastructural localization of tyrosine hydroxylase immunoreactivity in the rat diagonal band of Broca. J Neurosci Res 1991;30:498-511.
125. Pickel VM, Joh TH, Reis DJ. Ultrastructural localization of tyrosine hydroxylase in noradrenergic neurons of brain. Proc Natl Acad Sci U S A 1975;72:659-663.
126. Lee BR, Matsuo Y, Cashikar AG, Kamitani T. Role of Ser129 phosphorylation of α-synuclein in melanoma cells. J Cell Sci 2013;126:696-704.
127. Spillantini MG, Schmidt ML, Lee VM, et al. A-synuclein in Lewy bodies. Nature 1997;388:839-840.
128. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-244.
129. Machiya Y, Hara S, Arawaka S, et al. Phosphorylated a-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 2010;285:40732-40744.
130. Perez RG, Hastings TG. Could a loss of a-synuclein function put dopaminergic neurons at risk? J Neurochem 2004;89:1318-1324.